BioNTech's Gotistobart Extends Survival to 18.5 Months, but Comirnaty's Slide Keeps the Stock Under Pressure
Published on 09/20/2026 at 11:42 | Editorial boerse-global.de
BioNTech's pandemic-era windfall is fading, and the market is still learning to price what comes next. On Friday, the Mainz-based biotech's shares closed at EUR 83.80 on Xetra, down 2.6%, even as U.S. regulators cleared an updated version of its Covid vaccine targeting the dominant XFG strain — a reminder that good news in one part of the business no longer moves the whole story.
The stock now sits 21% below its 52-week high of EUR 105.80, and year-to-date it has managed only a modest gain of 3.0%. That muted performance captures the awkward in-between phase BioNTech occupies: no longer a pandemic phenomenon, not yet a proven oncology franchise.
A Survival Signal in Lung Cancer
The clearest evidence that the science can still deliver came from the company's oncology pipeline. Partnering with OncoC4, BioNTech reported Phase 1 results from the PRESERVE-003 trial for gotistobart in previously treated patients with metastatic squamous non-small cell lung cancer.
The antibody candidate achieved a median overall survival of 18.5 months, against 10.0 months for patients on standard docetaxel chemotherapy. With a data cutoff of July 17, 2026, the hazard ratio stood at 0.56 — a figure Reuters described as roughly doubling survival compared with the existing standard of care. For a company trying to convince investors that its mRNA expertise translates into solid-tumor therapies, the readout is a meaningful proof point.
Should investors sell immediately? Or is it worth buying BioNTech?
The Setbacks That Come With the Territory
Set against that win is the harsher reality of late-stage drug development. Roughly two weeks ago, BioNTech halted its Cevumeran colorectal cancer study after an independent panel concluded there was insufficient prospect of extending patients' lives. The decision served as a blunt reminder that even promising mRNA approaches offer no guarantee of therapeutic success once tested in larger patient populations.
That duality — a pipeline that giveth and taketh away — is precisely what makes the sector so difficult to value. Years of cash reserves once sufficed to underpin BioNTech's valuation. Now, clinical efficacy data and regulatory milestones carry the weight.
Analysts Trim Expectations as Revenue Base Erodes
The strategic pivot is unfolding against a deteriorating revenue backdrop. On September 8, BMO Capital Markets downgraded the stock from Outperform to Market Perform and cut its price target to $105 from $128. The brokerage pointed to an unexpectedly sharp erosion of revenue from Comirnaty, the Covid vaccine BioNTech sells with Pfizer.
BMO also flagged that robust risk-reduction data for the cancer candidate Pumitamig is not expected until 2028, while expectations for the iNeST program have been tempered. The dilemma is straightforward: legacy earnings are drying up faster than new drugs can reach the market. Although the FDA has approved the XFG-adapted Covid shot from Pfizer and BioNTech — laying the regulatory groundwork for the coming U.S. vaccination season — the segment's overall market volume remains structurally diminished. BioNTech's future will be decided not by booster doses but by late-stage trials against solid tumors.
Insider Sales Add to the Wariness
CEO Ugur Sahin's routine share sales have done little to calm nerves. On Friday, he disposed of additional stock under a trading plan established on June 3, 2026, in compliance with Rule 10b5-1. Combined with prior transactions, 64,000 shares were sold on Thursday and Friday. Such automated sales are standard practice in the industry, yet they reliably generate extra skepticism during periods of strategic uncertainty.
For investors, the takeaway is a return to old-fashioned discipline. Betting on BioNTech today means wagering on scientific evidence and the outcome of lengthy Phase 3 trials rather than on rapid vaccine billions. Those who stay committed are no longer backing a phenomenon — they are backing a conventional biotechnology company, with every risk that entails.
Ad
BioNTech Stock: New Analysis - 20 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
